Clinical Trials Logo

Filter by:
NCT ID: NCT05742425 Recruiting - Clinical trials for Unresectable Colon Cancer Peritoneal Metastases

Serplulimab Combined With FOLFIRI and Bevacizumab in the Treatment of Colon Cancer Peritoneal Metastases

Start date: March 2023
Phase: Phase 2
Study type: Interventional

Multicentric randomised trial. The goal of this clinical research study is to evaluate the efficacy and safety of serplulimab combined with FOLFIRI+bevacizumab in the treatment of pMMR/Ras/BRAF wild-type unresectable peritoneal metastasis of colon cancer.

NCT ID: NCT05742230 Recruiting - Heart Failure Clinical Trials

Effect of Henagliflozin on Cardiac Function in Type 2 Diabetes Patients With Chronic Heart Failure (HERO-HF)

HERO-HF
Start date: April 15, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the superiority of the effectiveness of Henagliflozin 10 milligram (mg) daily versus blank control in participants with type II diabetes (T2DM) and symptomatic heart failure (HF) in improving the overall Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (CSS).

NCT ID: NCT05742204 Recruiting - Lung Cancer Clinical Trials

Plasma Proteomic Biomarkers for Early Diagnosis of Lung Cancer

Start date: February 1, 2023
Phase:
Study type: Observational

We will identify plasma proteomics biomarkers for early diagnosis of lung cancer.

NCT ID: NCT05742126 Completed - Healthy Clinical Trials

A Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Dosed of HSK36273 in Healthy Volunteers

Start date: April 11, 2022
Phase: Phase 1
Study type: Interventional

This is a single-center, Phase 1, placebo and positive-controlled, randomized, partial-blind, integrated, sequential ascending dose / multiple ascending dose study.The safety, tolerability, pharmacokinetics and pharmacodynamics of multiple continuous IV infusion ascending doses of HSK36273 in healthy volunteers will be evaluated.

NCT ID: NCT05741905 Recruiting - Clinical trials for Acute Ischemic Stroke

Safety and Efficacy of Levofloxacin Combined With Intravenous Thrombolysis for Acute Ischemic Stroke

Start date: June 1, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the efficacy and safety of levofloxacin combined with intravenous thrombolysis in treating acute ischemic stroke

NCT ID: NCT05741684 Completed - Depression Clinical Trials

iCBT and ABM for Reducing Depressive Symptoms in Firefighters

Start date: April 1, 2022
Phase: N/A
Study type: Interventional

The study aimed to examine the impact of a combined internet-delivered Cognitive Behavioral Therapy (iCBT) and Attention Bias Modification (ABM) intervention to reduce depressive symptoms in firefighters. The study was a randomized controlled trial carried out in Kunming, China, and involved the recruitment of 138 active firefighters as participants. The intervention lasted for an 8-week duration, during which participants participated in ABM exercises on alternating days and concurrently underwent four modules of iCBT courses delivered through a smartphone application.

NCT ID: NCT05741359 Recruiting - Clinical trials for Non-hodgkin Lymphoma,B Cell

The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma

Start date: April 25, 2023
Phase: Phase 1
Study type: Interventional

This is a multi-center, single-arm, open-label clinical study, and the sample size is set to 12-18 subjects.

NCT ID: NCT05741099 Recruiting - COVID-19 Clinical Trials

Application and Research of Mesenchymal Stem Cells in Alleviating Severe Development of COVID-19 Infection

Start date: January 28, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This study is to evaluate the safety and efficacy of umbilical cord mesenchymal stem cells Therapy for COVID-19.

NCT ID: NCT05741086 Recruiting - Clinical trials for Stroke Patients With Symptomatic Intracranial Atherosclerotic Stenosis

Evolocumab Added to Statin Therapy in Symptomatic Intracranial Atherosclerotic Stenosis (EAST-ICAS)

EAST-ICAS
Start date: April 15, 2023
Phase: Phase 3
Study type: Interventional

The primary goal of the trial is to investigate whether the experimental arms (receiving the Proprotein Convertase Subtilisin-Kexin Type 9 [PCSK9] inhibitor Evolocumab plus statin) could cause more changes from baseline in intracranial atherosclerotic plaque and hemodynamic features during 1 year of follow-up, compared with the control arm (taking statin) in patients with recent stroke/transient ischemic attack (TIA) caused by intracranial artery stenosis.

NCT ID: NCT05741047 Completed - Clinical trials for Mild Cognitive Impairment

Comparative Effects of a2 Skim Milk on Mild Cognitive Impairment in Older Adults

Start date: March 7, 2023
Phase: N/A
Study type: Interventional

The aim of the study is to compare the effects of powdered skim milk containing A2 β-casein only versus conventional powdered skim milk containing A1 and A2 β-casein milk on cognition, inflammation, and dietary intake in adults aged 65-75 years.